Quick-Med Technologies, Inc. announced that the US Patent and Trademark Office (USPTO) has issued US Patent No. 7,473,474 to Quick-Med covering select uses of the NIMBUS technology. This patent stems from a provisional patent application filed with the USPTO in February 2004 by Quick-Med. The new patent, together with a previously issued patent and eleven additional pending patent applications plus foreign counterparts pending in Europe, Australia, Brazil, Canada, China, India, Japan, Mexico, and South Africa, provide broad coverage for NIMBUS, an innovative, next-generation antimicrobial technology. NIMBUS is different from other antimicrobial technology because of its permanent bond and its ability to be effective even in the presence of large amounts of body fluids which can “blind” other antimicrobials. The active agent is permanently bonded to the substrate, keeping the biocide from depletion while killing microbes (such as MRSA, VRE, and many others) that are present on the substrate and maintaining continuing antimicrobial performance. Being bound to the substrate keeps the antimicrobial at full strength; test results show that even in 90% serum, NIMBUS continues to kill microbes outperforming other antimicrobials. NIMBUS technology is well-suited for a wide range of healthcare and consumer applications. The company’s target applications include wound dressings, catheters and sutures, medical textiles, apparel, bed linens, incontinence products, persistent skin sanitizers, and adhesives.